Literature DB >> 1684733

Roles of neurotransmitter amino acids in seizure severity and experience in the genetically epilepsy-prone rat.

S M Lasley1.   

Abstract

This investigation was designed to compare seizure-naive and seizure-experienced genetically epilepsy-prone rats (GEPRs) in order to distinguish transmitter amino acid changes related to seizure severity from those associated with seizure experience. Moderate (GEPR-3) and severe (GEPR-9) seizure male GEPRs were divided into seizure-naive and seizure-experienced groups based on whether seizure-inducing acoustical stimuli had been presented between 45 and 60 days of age, and then were sacrificed at 76 +/- 3 days. gamma-Aminobutyric acid (GABA) concentrations were lower in both GEPR-3s and GEPR-9s compared to non-epileptic controls in each brain region examined. Aspartate content was elevated in 5 of 6 brain areas in GEPR-9s compared to non-epileptic controls, and in 3 regions was higher in GEPR-9s than in GEPR-3s. In contrast, taurine concentrations were higher in GEPR-3s than in non-epileptic controls in each region, and in 4 areas were higher in GEPR-3s than in GEPR-9s. Changes resulting from seizure experience consisted of increases in aspartate, glutamate and glycine in seizure-experienced compared to seizure-naive groups in inferior colliculus and in motor-sensory and frontal cortices. These findings suggest that the high levels of taurine in GEPR-3s and the elevated content of aspartate in GEPR-9s have roles as determinants of seizure severity. The low concentrations of GABA in both types of GEPRs are consistent with a role for this amino acid in determination of seizure susceptibility. Furthermore, the seizure-induced changes in aspartate and glutamate in both types of GEPRs support the concept that these excitatory amino acids mediate changes in seizure predisposition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684733     DOI: 10.1016/0006-8993(91)91215-m

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR).

Authors:  Yichien Lee; Olga C Rodriguez; Chris Albanese; Victor Rodrigues Santos; José Antônio Cortes de Oliveira; Ana Luiza Ferreira Donatti; Artur Fernandes; Norberto Garcia-Cairasco; Prosper N'Gouemo; Patrick A Forcelli
Journal:  Neurobiol Dis       Date:  2017-12-21       Impact factor: 5.996

2.  Glycine induces bidirectional modifications in N-methyl-D-aspartate receptor-mediated synaptic responses in hippocampal CA1 neurons.

Authors:  Xiao-Yan Zhang; Fang Ji; Ning Wang; Lin-Lin Chen; Tian Tian; Wei Lu
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

3.  Role of glycine receptors in glycine-induced LTD in hippocampal CA1 pyramidal neurons.

Authors:  Rong-Qing Chen; Shan-Hui Wang; Wen Yao; Jing-Jing Wang; Fang Ji; Jing-Zhi Yan; Si-Qiang Ren; Zheng Chen; Su-Yi Liu; Wei Lu
Journal:  Neuropsychopharmacology       Date:  2011-05-18       Impact factor: 7.853

4.  Developmental PCB Exposure Increases Audiogenic Seizures and Decreases Glutamic Acid Decarboxylase in the Inferior Colliculus.

Authors:  Suren B Bandara; Paul A Eubig; Renee N Sadowski; Susan L Schantz
Journal:  Toxicol Sci       Date:  2015-11-04       Impact factor: 4.849

Review 5.  Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.

Authors:  Andrea de Bartolomeis; Mirko Manchia; Federica Marmo; Licia Vellucci; Felice Iasevoli; Annarita Barone
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

6.  Glutamatergic Fate of Neural Progenitor Cells of Rats with Inherited Audiogenic Epilepsy.

Authors:  Alexandra A Naumova; Ekaterina A Oleynik; Elena V Chernigovskaya; Margarita V Glazova
Journal:  Brain Sci       Date:  2020-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.